Puretech Health
PureTech Health, a pioneering biopharmaceutical company headquartered in the United States, focuses on developing innovative therapies for complex diseases. Founded in 2015, PureTech has established itself as a leader in the healthcare industry, with a strong emphasis on advancing drug development in areas such as neuroscience, immunology, and gastrointestinal health. The company is renowned for its unique approach to drug discovery, leveraging its proprietary platform to identify and develop novel therapeutics. With a robust pipeline of products, including treatments for neurodegenerative disorders and immune-mediated diseases, PureTech Health is well-positioned in the market. Its commitment to addressing unmet medical needs has garnered recognition, making it a notable player in the biopharmaceutical landscape.
DitchCarbon Score
How does Puretech Health's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Puretech Health's score of 43 is higher than 67% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Puretech Health's reported carbon emissions
In 2023, PureTech Health reported total carbon emissions of approximately 276,200 kg CO2e. This figure includes 3,900 kg CO2e from Scope 1 emissions, 57,000 kg CO2e from Scope 2 emissions (market-based), and 107,700 kg CO2e from Scope 3 emissions. The combined Scope 1 and 2 emissions totalled about 168,500 kg CO2e. Comparatively, in 2022, the company’s total emissions were significantly higher at about 665,000 kg CO2e, with Scope 1 emissions at 10,600 kg CO2e, Scope 2 emissions (market-based) at 402,600 kg CO2e, and Scope 3 emissions at 251,900 kg CO2e. This indicates a substantial reduction in total emissions year-on-year. PureTech Health has not disclosed specific reduction targets or initiatives under the Science Based Targets initiative (SBTi) or other climate pledges. The absence of documented reduction targets suggests that while the company is actively reporting its emissions, it may not yet have formalised commitments to reduce its carbon footprint in line with industry standards. The emissions data is sourced directly from PureTech Health plc, with no cascading from a parent organisation. The company continues to monitor and report its emissions, contributing to transparency in its climate impact.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|
| Scope 1 | 25,900 | 000,000 | 00,000 | 0,000 |
| Scope 2 | 120,900 | 000,000 | 000,000 | 00,000 |
| Scope 3 | 232,700 | 000,000 | 000,000 | 000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Puretech Health is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
